Lmr Partners LLP Atea Pharmaceuticals, Inc. Transaction History

Lmr Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.35 - $6.17 $21,562 - $30,584	-4,957 Reduced 14.77%	28,595 $137,000
Q3 2022 Nov 14, 2022	SELL	$5.49 - $8.79 $193,615 - $309,996	-35,267 Reduced 51.25%	33,552 $191,000
Q2 2022 Aug 15, 2022	BUY	$5.33 - $8.18 $213,988 - $328,410	40,148 Added 140.03%	68,819 $489,000
Q1 2022 May 16, 2022	BUY	$5.5 - $9.19 $157,690 - $263,486	28,671 New	28,671 $207,000

112

50.9M

7.6K

38.7K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $257M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.